Skip to Content

Join the 'Psoriasis' group to help and get support from people like you.

Psoriasis News

Related terms: Erythrodermic Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Palmo-plantar Psoriasis, Psoriasis vulgaris, Pustular Psoriasis

Psoriasis Tied to Obesity, Type 2 Diabetes

Posted 7 days ago by Drugs.com

WEDNESDAY, April 27, 2016 – The chronic skin disease psoriasis may be linked to excess weight and type 2 diabetes, results of a new study suggest. Danish researchers found that people with type 2 diabetes had more than 50 percent greater odds of having psoriasis compared to people without diabetes. The study also found that the rate of psoriasis went up with increasing weight. For example, obese people with a body mass index (BMI) over 35 had almost double the odds of psoriasis than normal weight people did. BMI is a body fat measurement based on height and weight. A BMI of 30 or over is considered obese. Exactly how these conditions might be connected isn't clear, but the study authors suggested that genetics, smoking, drinking alcohol, or inflammation might play a role. "Psoriasis is a complex disorder," said lead researcher Dr. Ann Sophie Lonnberg, of the University of Copenhagen. ... Read more

Related support groups: Diabetes, Type 2, Obesity, Psoriasis, Plaque Psoriasis, Psoriatic Arthropathy

Psoriasis May Raise Risk for Aneurysms in Abdomen: Study

Posted 19 days ago by Drugs.com

THURSDAY, April 14, 2016 – Psoriasis patients may face a higher risk of an abdominal aortic aneurysm, though the overall odds of experiencing this potentially deadly blood vessel rupture are small, new research shows. The Danish scientists also found that the more severe the psoriasis – a chronic autoimmune condition characterized by scaly, red patches of skin – the more likely a person will develop an abdominal aortic aneurysm. They believe the two conditions share overlapping inflammatory processes in the body. "The association between [abdominal aortic aneurysm] and psoriasis has not been examined before, but we are not surprised by seeing a heightened risk in our study," said lead researcher Dr. Usman Khalid, a fellow in the department of cardiology at Herlev and Gentofte Hospital in Hellerup, Denmark. "Our results add to the evidence that there is an increased risk of various ... Read more

Related support groups: Psoriasis, Plaque Psoriasis, Aortic Aneurysm

Inflectra Approved as 'Biosimilar' to Remicade

Posted 7 Apr 2016 by Drugs.com

WEDNESDAY, April 6, 2016 – The U.S. Food and Drug Administration has approved its second-ever "biosimilar" drug, Inflectra, for adults with Crohn's disease, rheumatoid arthritis or chronic plaque psoriasis, among other prescribed uses. In a media release, the agency said Inflectra was biosimilar to Janssen Biotech's Remicade (infliximab), first licensed in 1998. A biosimilar drug is sanctioned based on its maker's ability to show that it is "highly similar" to an already-approved biological drug that is generally derived from a living organism, such as a person, animal, microorganism or yeast, the FDA said. The maker of a biosimilar drug also must prove that the product has no "clinically meaningful difference" in safety and effectiveness from the original drug, and that the newer product has only "minor differences in clinically inactive components" from the original. Inflectra's most ... Read more

Related support groups: Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Remicade, Ulcerative Colitis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Ulcerative Colitis - Active, Crohn's Disease - Acute, Plaque Psoriasis, Ulcerative Colitis - Maintenance, Infliximab, Inflectra

FDA Approves Inflectra (infliximab-dyyb) a Biosimilar to Remicade

Posted 7 Apr 2016 by Drugs.com

April 5, 2016 – The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA. Inflectra is biosimilar to Janssen Biotech, Inc.’s Remicade (infliximab), which was originally licensed in 1998. Inflectra is approved and can be prescribed by a health care professional for the treatment of: adult patients and pediatric patients (ages six years and older) with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy; adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy; patients with moderately to severely active rheumatoid arthritis in combination with methotrexate; patients with active ankylosing spondylitis (arthritis of ... Read more

Related support groups: Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Remicade, Ulcerative Colitis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Infliximab, Inflectra

FDA Approves Taltz (ixekizumab) for Plaque Psoriasis

Posted 23 Mar 2016 by Drugs.com

March 22, 2016 – The U.S. Food and Drug Administration today approved Taltz (ixekizumab) to treat adults with moderate-to-severe plaque psoriasis. Psoriasis is a skin condition that causes patches of skin redness and flaking. Psoriasis is an autoimmune disorder that occurs more commonly in patients with a family history of the disease, and most often begins in people between the ages of 15 and 35. The most common form of psoriasis is plaque psoriasis, in which patients develop thick, red skin with flaky, silver-white scales. “Today’s approval provides patients suffering from plaque psoriasis with another important treatment option to help relieve the skin irritation and discomfort from the condition,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research. Taltz’s active ingredient is an antibody (ixekizumab) that bi ... Read more

Related support groups: Psoriasis, Plaque Psoriasis, Taltz, Ixekizumab

Safe Treatments Available for Expectant Moms' Skin Conditions

Posted 4 Mar 2016 by Drugs.com

FRIDAY, March 4, 2016 – There are a number of safe and effective ways to treat chronic skin conditions in pregnant women, a dermatologist says. "If there is a way to manage your skin condition without medication during pregnancy, that is the preferred option," said Dr. Jenny Eileen Murase, an assistant clinical professor of dermatology at the University of California, San Francisco. "If you have a condition that does require medication, however, a board-certified dermatologist can help you identify a treatment that's safe for both you and your baby," she added in an American Academy of Dermatology news release. The release was timed to coincide with the academy's annual meeting, which starts Friday in Washington, D.C. Eczema is the most common rash dermatologists see in pregnancy, Murase said. "Expectant mothers often see their existing eczema get worse or have a flare for the first ... Read more

Related support groups: Clindamycin, Psoriasis, Eczema, Retin-A, Epiduo, Cleocin, Benzoyl Peroxide, Acne Treatment, Adapalene, Salicylic Acid, Plaque Psoriasis, Differin, Finacea, Aczone, Compound W, Benzaclin, Duac, Duofilm, Atralin, Ziana

Promius Pharma Receives FDA Approval for Sernivo (betamethasone dipropionate) Spray

Posted 10 Feb 2016 by Drugs.com

HYDERABAD, India & PRINCETON, N.J., February 07, 2016 --(BUSINESS WIRE)--Dr. Reddy’s announced today that its US subsidiary, Promius Pharma, LLC, U.S. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), has received approval for Sernivo (betamethasone dipropionate) Spray, 0.05% from the U.S. Food and Drug Administration (FDA). Sernivo Spray, a prescription topical steroid, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older. The commercial launch of the product is planned for the coming quarter. Commenting on the approval, G V Prasad, Co-Chairman and CEO, Dr. Reddy’s Laboratories said, “The FDA approval of Sernivo Spray is a significant milestone for Promius, as it validates our committed efforts and resources to developing differentiated dermatology products from concept to commercial launch. We are delighted to receive a first round FDA appro ... Read more

Related support groups: Psoriasis, Plaque Psoriasis, Sernivo

Novartis Receives FDA Approval for Cosentyx (secukinumab) to Treat Patients with Ankylosing Spondylitis and Psoriatic Arthritis

Posted 17 Jan 2016 by Drugs.com

EAST HANOVER, N.J., Jan. 15, 2016 Novartis announced today that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). AS and PsA are both life-long, painful and debilitating inflammatory diseases that affect the joints and/or spine. If not treated effectively, both conditions can lead to irreversible joint and/or spinal bone damage caused by years of inflammation.2,3,4 With these new approvals, Cosentyx is now the first and only interleukin-17A (IL-17A) antagonist approved for AS, as well as moderate to severe plaque psoriasis and PsA, which impacts as many as 30% of patients with psoriasis.5 Cosentyx was approved for adult patients with moderate to severe plaque psoriasis in January 2015 and more than 13,000 patients with this ... Read more

Related support groups: Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Cosentyx, Secukinumab

New Drug for Severe Form of Arthritis Shows Promise in Trial

Posted 24 Dec 2015 by Drugs.com

WEDNESDAY, Dec. 23, 2015 – A drug recently approved for the skin condition psoriasis may also help people with a debilitating form of arthritis that attacks the spine, a new clinical trial finds. The condition, called ankylosing spondylitis, causes inflammation around the vertebrae, which can lead to chronic pain and stiffness in the back and neck – and, in some people, eventually cause some vertebrae to fuse into an immobile position. In the new trial, researchers found that a drug called secukinumab (Cosentyx) helped control symptoms in 61 percent of spondylitis patients who were given the highest dose. Experts said the results, published Dec. 24 in the New England Journal of Medicine, could open up a new option for managing spondylitis. And new options are needed, said Dr. Scott Zashin, a fellow with the American College of Rheumatology who was not involved in the study. ... Read more

Related support groups: Psoriasis, Ankylosing Spondylitis, Plaque Psoriasis, Cosentyx, Psoriatic Arthropathy

'Designer Cells' Show Promise Against Psoriasis in Lab Mice

Posted 16 Dec 2015 by Drugs.com

WEDNESDAY, Dec. 16, 2015 – Scientists say they've engineered cells capable of automatically detecting and treating psoriasis flare-ups in lab mice – in an early step toward a "precision" therapy for the chronic skin disease. Experts said they were "excited" by the findings, reported Dec. 16 in the journal Science Translational Medicine. But they also cautioned that a lot of work lies ahead. In the United States, more than 5 million people have psoriasis, according to the U.S. National Institutes of Health. The disease arises from an abnormal immune system response that triggers a rapid turnover of skin cells. As a result, people with psoriasis periodically develop thick, scaly patches on the skin that can be itchy or painful. When psoriasis is milder, skin treatments or UV light therapy can be enough to treat the symptoms. But people with more severe psoriasis often need pills or ... Read more

Related support groups: Psoriasis

LEO Pharma Announces U.S. Approval of Enstilar Foam (calcipotriene/betamethasone dipropionate) for Plaque Psoriasis

Posted 21 Oct 2015 by Drugs.com

Ballerup, Denmark 19 October, 2015: LEO Pharma announced today that the U.S. Food and Drug Administration (FDA) has approved Enstilar (calcipotriene/betamethasone dipropionate 50 micrograms/g / 0,5 mg/g) Foam for the treatment of psoriasis vulgaris in patients 18 years of age or older in the United States.1 Enstilar is a once-daily, alcohol-free topical treatment.1 “We are very pleased by the U.S. approval of Enstilar and believe it will provide patients with the type of treatment option that they are looking for,” said Gitte Aabo, President and CEO of LEO Pharma. “At LEO Pharma, we are committed to providing patients with innovative, new solutions and we believe the foam formulation of Enstilar can help patients living with psoriasis.” Enstilar was developed to treat patients with psoriasis vulgaris2,3 – the most common clinical form of psoriasis.4 The U.S. approval of Enstilar was ... Read more

Related support groups: Psoriasis, Plaque Psoriasis, Enstilar, Betamethasone/Calcipotriene

Psoriasis, Cold Sores Most Stigmatized Skin Disorders: Survey

Posted 9 Oct 2015 by Drugs.com

FRIDAY, Oct. 9, 2015 – Psoriasis and cold sores top the list of stigmatized skin conditions, a new survey indicates, but experts say much of the ill will directed at sufferers is misguided. Surveying 56 people, Boston researchers found that nearly 61 percent wrongly thought psoriasis – which produces widespread, scaly red skin lesions – looked contagious, and about nine in 10 said they would pity a person who had it. About four in 10 said herpes simplex, or cold sore, is the most bothersome skin condition. "We knew from other studies that psoriasis seemed to be more stigmatizing than other skin diseases, [and] we did this study to try to find out why," said study author Dr. Alexa Kimball, a dermatology professor at Harvard Medical School. "We suspected that the fact that it looked infectious could be part of the reason people reacted strongly to it, but we didn't expect that reaction ... Read more

Related support groups: Acne, Psoriasis, Eczema, Cold sores, Warts, Rosacea, Plaque Psoriasis, Vitiligo, Tinea Versicolor, Herpes Simplex Labialis, Minor Skin Conditions, Minor Skin Irritation

Worse Psoriasis, Less Healthy Arteries, Study Finds

Posted 8 Oct 2015 by Drugs.com

THURSDAY, Oct. 8, 2015 – The skin disorder psoriasis appears linked with artery inflammation, raising the odds for heart disease, a new study says. "As the amount of psoriasis increases, the amount of blood vessel inflammation increases," said senior investigator Dr. Nehal Mehta, a clinical investigator with the U.S. National Heart, Lung, and Blood Institute. His team also found that even mild psoriasis may indicate an increased risk for heart attack and stroke. Just one psoriasis skin patch, or plaque, "might be biologically active, causing low-grade inflammation and starting a cascade, speeding up their blood vessel disease," Mehta said. "People really should know that psoriasis is not just a cosmetic disease," he added. However, these study findings only show an association between psoriasis and blood vessel inflammation, not a direct cause-and-effect relationship, Mehta said. His ... Read more

Related support groups: Methotrexate, Psoriasis, Inflammatory Conditions, Plaque Psoriasis, Coronary Artery Disease (CAD), Soriatane, Dovonex, Acute Coronary Syndrome, Tazorac, Oxsoralen, Acitretin, Taclonex, Calcipotriene, Tazarotene, Resorcinol, Acute Coronary Syndrome - Prophylaxis, Anthralin, Vectical, Dritho-Scalp, Psoriatec

Psoriasis, Depression Often Go Hand in Hand: Study

Posted 1 Oct 2015 by Drugs.com

THURSDAY, Oct. 1, 2015 – Regardless of severity, patients with the often disfiguring skin condition psoriasis face an elevated risk for depression, new research suggests. The depression risk may be driven more by concerns about appearance than by the actual status of the skin, said study author Dr. Roger Ho, an assistant professor in the department of dermatology at New York University School of Medicine. "One small area of [psoriasis] involvement might mean a lot more to one person than an area three times the size for another person," said Ho. "I think the location of skin lesions, such as lesions in a more visible area or lesions in an area that impairs daily functioning, might play a bigger role." Between 2 percent and 4 percent of North Americans have psoriasis, Ho said. The autoimmune disorder causes red, raised patches of skin covered with silvery-white scales. These patches ... Read more

Related support groups: Depression, Major Depressive Disorder, Psoriasis, Psoriatic Arthritis, Postpartum Depression, Dysthymia, Plaque Psoriasis, Psoriatic Arthropathy

2 Experimental Drugs Offer Hope Against Psoriasis: Studies

Posted 30 Sep 2015 by Drugs.com

WEDNESDAY, Sept. 30, 2015 – Two experimental drugs show promise in treating psoriasis and a related condition, psoriatic arthritis, new studies report. The drugs, brodalumab and secukinumab (Cosentyx), represent a new approach to treatment, said Michael Siegel, director of research programs at the National Psoriasis Foundation. "These studies show how targeting parts of the immune system can have great effects, and that's really exciting for our patients," said Siegel, who wasn't involved in the research. Psoriasis, a chronic autoimmune condition, causes raised red patches of skin topped with silvery scales. These patches usually appear on the scalp, elbows, knees, face, lower back, hands and feet. Psoriatic arthritis is a form of the disease that includes joint pain, stiffness and swelling. The study findings appear in the Oct. 1 issue of the New England Journal of Medicine. In one ... Read more

Related support groups: Psoriasis, Psoriatic Arthritis, Plaque Psoriasis, Cosentyx, Secukinumab, Psoriatic Arthropathy

Page 1 2 3 4 5 6 Next

Ask a Question

Further Information

Related Condition Support Groups

Plaque Psoriasis, Psoriatic Arthropathy, Dermatological Disorders

Related Drug Support Groups

prednisone, methotrexate, Humira, methylprednisolone, Remicade, dexamethasone, triamcinolone, clobetasol, Therapeutic, view more... fluocinonide, Clobex, cyclosporine, desonide, Stelara, Kenalog, hydroxyurea, Psoriasin, desoximetasone, Elocon, Topicort, Soriatane, Dovonex, Lidex, Tazorac, Halog, Kenalog-10, Olux, infliximab, Cordran, Cortizone-10, coal tar, Acthar, Cloderm, Neoral, Cordran Tape, feverfew, Locoid, Analpram-HC, halobetasol, Acth, Synalar, Deltasone, acitretin, Taclonex, Vanos, etanercept, Acthar Gel, HP, Eczema Cream, Olux-E, adalimumab, Kenalog-40, Dermovate, Cortaid, calcipotriene, Temovate, tazarotene, methoxsalen, Aclovate, Aristocort A, Proctofoam HC, Anucort-HC, Locoid Lipocream, Vectical, Ultravate, Halog-E, Hytone, Verdeso, halcinonide, anthralin, hydrocortisone / pramoxine, Gengraf, resorcinol, Cortaid Maximum Strength, Desonate, Triderm, Aristocort R, corticotropin, Oxsoralen-Ultra, diflorasone, Liquid Pred, Dermatop, Sterapred DS, Proctozone HC, Drithocreme, Taclonex Scalp, Dermarest Dricort, Cortane, Hemorrhoidal HC, Enstilar, Methotrexate LPF Sodium, alclometasone, Proctosol-HC, Coal Tar Strong, Aquanil HC, Pandel, X-Seb T Plus, DHS Tar Shampoo, Neutrogena T / Derm, Corticaine, Hycort, Cortizone-10 Plus, Encort, Trexall, DesOwen, Capex, Psoriatec, Sterapred, Embeline, Nutracort, Pramosone, Fototar, Trianex, Instacort, Dritho-Scalp, Anti-Dandruff, Topicort LP, ustekinumab, Amevive, Aristospan, Cyclocort, Proctocort, Hi-Cor, Procto-Kit 2.5%, Nogenic HC, Gly-Cort, Dermolate, Anuprep-HC, HC Pram, Dermol HC, Halac, Anthraforte, Recort Plus, Scalp-Aid, Cort-Dome, Genasone / Aloe, Instacort 10, MG217 Psoriasis, Sarnol-HC, Carb-O-Lac HP, Delcort, Rederm, Scalp-Cort, Caldecort, Tarsum, Lacticare-HC, Ala-Scalp HP, Rectasol-HC, Cotacort, Penecort, Anumed-HC, Hemril-HC Uniserts, Hydrocort cream, Ala-Cort, Pediaderm TA, Inflectra, Acticort 100, Aloe Cort, Calcitrene, Pediaderm HC, Cortaid with Aloe, Sorilux, Anutone-HC, Anurx-HC, Beta HC, Corticreme, Cortizone for Kids, Dermagesic, PC Tar, Resinol, Scytera, MD Hydrocortisone, Zithranol-RR, Ultravate PAC, Olux / Olux-E Kit, OraMagic Rx, Temovate E, Dermotic, Fluocinonide-E, Scalacort, Procto-Kit 1%, Derma-Smoothe / FS (Scalp), Synalar Ointment, Carmol HC, Keratol HC, Cormax Scalp, Analpram E, Rasuvo, Otrexup, Synalar TS, Hydrocortisone 1% In Absorbase, Z-Xtra, Itch-X Lotion, Halonate, Neutrogena T-Scalp, Dermtex HC, Clodan, Anuzone HC, Zithranol, Cortizone-5, Pramosone E, Proctocream-HC, Nupercainal HC 1%, Dermarest Plus Anti-Itch, Hemril-30, Proctozone-H, NuZon, Gynecort Maximum Strength, Procto-Pak 1%, Soriatane CK, Anthrascalp, Cortaid Intensive Therapy, Carb-O-Lac5, Proctosert HC, Ala-Scalp, U-Cort, Ivocort, Tegrin Medicated, A-Fil, Micanol, Tegison, Temovate Emollient, Embeline E, Cormax, Anthra-Derm, Clinacort, Meticorten, Folex PFS, Orasone, Prednicen-M, Prednicot, Clobevate, Delonide, FS Shampoo, Flurosyn, Synalar-HP, Licon, Fluex, Dermacin, Synemol, Fluonid, Psorcon, Florone, Florone E, Psorcon E, ApexiCon E, 8-MOP, Scalpicin, etretinate, efalizumab, flurandrenolide, prednicarbate, benzocaine / pyrilamine / zinc oxide, trioxsalen, coal tar / salicylic acid / sulfur, coal tar / salicylic acid, amcinonide, alefacept, ammonium lactate / urea, betamethasone / calcipotriene, clocortolone, ammonium lactate / halobetasol, MG217 Medicated Tar, Derma-Smoothe / FS, Raptiva, Lidex-E, Cordran SP, ProctoCare-HC, Epifoam, Maxiflor, Apexicon, Doak Tar, Medotar, Ionil T, Tridesilon, LoKara, Triacet, Aricin, Alphosyl 2 in 1, Alphosyl, Carbo-Dome, Doak Oil Forte, Orion Coal Tar, Apha Keri Tar, Clinitar, Psoriderm, Elta Tar, Cutar, Reme-T, Exorex, Polytar Mild, Linotar, Apha Keri Tar Gel, Cort-Dome High Potency, Ultralytic, Cetacort, Dermacort, Aeroseb-HC, Westcort, Ultralytic 2, Utralytic, Linotar Gel 3, Linotar Gel 2, Pinetarsol Tar, R A Acne, Dovobet, Doctar, Polytar, Rectocort HC, Zone-A Forte, Novacort, Hydropram, Zetar, HC Pramoxine, Enzone, Zone-A, Flutex, Delta-Tritex, Rx Triamcinolone, Cinalog, Cinolar, G-TAR, Zeprime Tar Emulsion, Doak Tar Oil, Oxipor VHC, Pentrax Gold, Tegrin Medicated Soap, Psorigel, Theraplex T, Betatar Gel, Neutrogena T / Gel, Ionil T Plus, Pentrax, Estar, Balnetar, Texacort